A biotech firm specialising in therapies for inflammatory diseases and cancer relating to the liver has jumped in value after it submitted a patent application for the potential use of one of its drugs in the fight against Covid-19.
Tiziana Life Sciences believes that nasal administration of Foralumab can be used to reduce respiratory failure in Covid-19 patients. Shares in Tiziana, which is listed on Nasdaq as well as London’s AIM, rose 18% to 224p.